1. Home
  2. TEI vs FULC Comparison

TEI vs FULC Comparison

Compare TEI & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TEI

Templeton Emerging Markets Income Fund Inc.

HOLD

Current Price

$6.64

Market Cap

310.3M

Sector

Finance

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.86

Market Cap

285.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TEI
FULC
Founded
1993
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
310.3M
285.4M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
TEI
FULC
Price
$6.64
$3.86
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$16.38
AVG Volume (30 Days)
137.5K
1.7M
Earning Date
01-01-0001
04-27-2026
Dividend Yield
10.51%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.75
$2.83
52 Week High
$7.00
$15.74

Technical Indicators

Market Signals
Indicator
TEI
FULC
Relative Strength Index (RSI) 42.39 52.48
Support Level $6.24 $3.44
Resistance Level $6.68 $3.96
Average True Range (ATR) 0.08 0.10
MACD -0.01 0.01
Stochastic Oscillator 0.00 71.67

Price Performance

Historical Comparison
TEI
FULC

About TEI Templeton Emerging Markets Income Fund Inc.

Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: